News Agency
The Times

Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity

  • Written by PR Newswire

The collaboration will accelerate the global development of LAE102, a novel Activin Receptor Type 2 A (ActRIIA) Antagonistic Monoclonal Antibody (mAb) for muscle-preserving weight loss in Obesity

LOS ANGELES, Nov. 20, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK) ("Laekna"), a global biotech company focused on novel drug development for...

Read more: Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal...

Why Businesses Rely On Accountants in Melbourne For Financial Success

Managing finances effectively is essential for individuals, business owners, investors, and growing organisations. Financial decisions influence profitability, compliance, cash flow, and long-term wealth creation, making professional financial guidance an important part of successful planning. Many individuals and businesses choose to... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion